结直肠癌肝转移新辅助治疗研究进展

doi:10.3877/cma.j.issn.2095-3224.2018.04.012

结直肠癌的发病率及死亡率在全世界范围内逐年上升，其主要的死亡原因是肝转移。现代医学技术快速发展推动了诊治理念不断更新。个体化治疗及多学科综合治疗协作组（MDT）诊治理念的提出，外科技术以及局部治疗的迅速发展，使患者的生存期得以明显延长。结直肠癌肝转移新辅助治疗的应用有助于降低肿瘤分期，提高手术切除率，进而转化为患者生存获益，这一点在其他实体瘤中也已得到证实。但新辅助治疗是否延长所有患者生存期以及患者能否从局部治疗中获益仍存在争议，本文就结直肠癌肝转移新辅助治疗研究进展进行综述。

关键词: 结直肠肿瘤, 肿瘤转移, 新辅助治疗, 结直肠癌肝转移, 全身治疗, 局部治疗, 生存期

The incidence and mortality rates of colorectal cancer are continually increasing worldwide. The main cause of death is liver metastasis. Rapid development of modern medical technology contribute to the update of diagnosis concept and treatment. With the ideas of personalized treatment and multidisciplinary team are put forward and rapid development of surgical skill and local treatment, the over survival time has been extended significantly. The application of colorectal liver metastases neoadjuvant therapy helps to reduce the tumor stage, improve the resection rate, and then benefit the patient. This has also been confirmed in other solid tumors. But whether neoadjuvant therapy can improve overall survival or all patients could benefit from local treatment is still controversial. The research progress on colorectal cancer liver metastasis neoadjuvant therapy is reviewed in this paper.

Key words: Colorectal neoplasms, Neoplasm metastasis, Neoadjuvant therapy, Colorectal liver metastases, Systemic therapy, Local treatment, Overall survival

表1 可切除CRLM患者新辅助化疗疗效相关临床研究

相关研究	年限	治疗方法（n）	3-y OS（%）	5-y OS（%）
Araujo^[10]	2013	NEO（n=175）	74.0	56.0
		SG（n=236）	78.0	60.0
Booney^[11]	2015	NEO（n=693）	72.0	N/A
		SG（n=608）	74.0
Oh^[12]	2013	NEO（n=15）	44.0	N/A
		SG（n=15）	55.7
Pinto^[13]	2012	NEO（n=334）	59.0	43.0
		SG（n=342）	71.0	55.0

表1 可切除CRLM患者新辅助化疗疗效相关临床研究

相关研究	年限	治疗方法（n）	3-y OS（%）	5-y OS（%）
Araujo^[10]	2013	NEO（n=175）	74.0	56.0
		SG（n=236）	78.0	60.0
Booney^[11]	2015	NEO（n=693）	72.0	N/A
		SG（n=608）	74.0
Oh^[12]	2013	NEO（n=15）	44.0	N/A
		SG（n=15）	55.7
Pinto^[13]	2012	NEO（n=334）	59.0	43.0
		SG（n=342）	71.0	55.0

表2 新辅助化疗联合西妥西单抗疗效的相关临床研究

研究	患者人群	数量	治疗组/对照组	R0切除率
Ye^[17]	KRAS-w最初不可切除	138	西妥西单抗联合化疗/单纯化疗	25.7% vs 7.4%
Xu^[18]	KRAS-w最初不可切除	93	西妥西单抗联合化疗/单纯化疗	26.7% vs 6.3%
Uetake^[19]	KRAS-w最初不可切除	45	贝伐珠单抗联合化疗	44.4%
Cui^[20]	CRLM	535	贝伐珠单抗联合化疗	49.2%
Garcia^[21]	可切除CRLM	20	贝伐珠单抗联合化疗	90%
Gruenerger^[22]	可切除CRLM	45	贝伐珠单抗联合化疗	97%

表2 新辅助化疗联合西妥西单抗疗效的相关临床研究

研究	患者人群	数量	治疗组/对照组	R0切除率
Ye^[17]	KRAS-w最初不可切除	138	西妥西单抗联合化疗/单纯化疗	25.7% vs 7.4%
Xu^[18]	KRAS-w最初不可切除	93	西妥西单抗联合化疗/单纯化疗	26.7% vs 6.3%
Uetake^[19]	KRAS-w最初不可切除	45	贝伐珠单抗联合化疗	44.4%
Cui^[20]	CRLM	535	贝伐珠单抗联合化疗	49.2%
Garcia^[21]	可切除CRLM	20	贝伐珠单抗联合化疗	90%
Gruenerger^[22]	可切除CRLM	45	贝伐珠单抗联合化疗	97%

[1]	Weitz J, Koch M, Debus J, et al. Colorectal cancer [J]. Lancet, 2005, 365(9454): 153-165.
[2]	Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxici-ties in patients with solid tumors treated with everolimus; asystematic review and meta-analysis [J]. Expert Rev Anti-cancer Ther, 2014, 14(12): 1529-1536.
[3]	Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorec-tal cancer: ESMO ClinicalPractice Guidelines for treatment [J]. Ann Oncol, 2010, 21(Suppl 5): v93-97.
[4]	O′Reilly DA, Poston GJ. Colorectal liver metastases: current and fu-ture perspectives [J]. Future Oncol, 2006, 2(4): 525-531.
[5]	中华医学会外科学分会胃肠外科学组中华医学会外科学分会结直肠肛门外科学组. CRLM诊断和综合治疗指南(V2013) [J]. 中华胃肠外科杂志, 2013, 16(8): 635-644.
[6]	Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer [J]. Annals of Oncology Official Journal of the European Society for Medical Oncology, 2016, 27(8): 1386.
[7]	Hellman S, Weichselbaum RR. Oligometastases [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 1995, 13(1): 8-10.
[8]	黄忠诚, 苏冀. CRLM的转化治疗策略 [J/CD]. 中华结直肠疾病电子杂志, 2013, (5): 217-220.
[9]	中华人民共和国卫生和计划生育委员会医政医管局. 中国结直肠癌诊疗规范(2015版) [J]. 中华消化外科杂志, 2015, 14(10): 506-523.
[10]	Araujo R, Gonen M, Allen P, et al. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer [J]. Annals of Surgical Oncology, 2013, 20(13): 4312.
[11]	Bonney GK, Coldham C, Adam R, et al. Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey [J]. Journal of Surgical Oncology, 2015, 111(6): 716.
[12]	Oh SY, Kim DY, Kim YB, et al. Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases [J]. Journal of Surgical Research, 2013, 182(2): 257.
[13]	Pinto MH, Barroso E, de Jong MC, et al. Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter? [J]. Journal of Surgical Oncology, 2012, 105(6): 511.
[14]	Zhu D, Zhong Y, Wei Y, et al. Effect of neoadjuvant che-moherapy in paitents with resectable colorectal live me-tastases [J]. PLoS One, 2014, 9(1): e86543.
[15]	Ayez N, Stok EPVD, Grünhagen DJ, et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator [J]. European Journal of Surgical Oncology, 2015, 41(7): 859-867.
[16]	邵仟仟, 林国乐. 2017. V1版《NCCN结直肠癌诊治指南》更新解读 [J]. 中国全科医学, 2017, 20(6): 635-638.
[17]	Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2013, 31(16): 1931-1938.
[18]	Xu J, Ren L, Wei Y, et al. Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): a retrospective biomarker analysis from a Chinese trial [J]. Annals of Oncology, 2016, 27(suppl_6): 541.
[19]	Uetake H, Yasuno M, Ishiguro M, et al. A multicenter phase Ⅱ trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808) [J]. Annals of Surgical Oncology, 2015, 22(3): 908-915.
[20]	Cui CH, Huang SX, Qi J, et al. Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis [J]. Oncotarget, 2015, 6(41): 44005.
[21]	Pilar GA, Ana F, Silvia G, et al. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents [J]. Targeted Oncology, 2015, 10(4): 453.
[22]	Gruenberger T, Laengle F, Thaler J, et al. Perioperative chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer; a multicenter, single arm phaseⅠ/Ⅱ trial: asso lm1 [C]// World Congress on Gastrointestinal Cancer of the. 2012: 19-20.
[23]	Primrose J, Falk S, Finchjones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial [J]. Lancet Oncology, 2014, 15(6): 601-611.
[24]	Anand A, Anand N, Anand A. Re: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer [J]. Journal of the National Cancer Institute, 1996, 88(12): 838-839.
[25]	Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? [J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2007, 25(35): 5649-5654.
[26]	Wicherts DA, Haas RJD, Azoulay D. Authors′ reply: Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases [J]. British Journal of Surgery, 2010, 97(2): 240-250.
[27]	He N, Jin QN, Wang D, et al. Radiofrequency ablation vs. hepatic resection for resectable colorectal liver metastases [J]. Journal of Huazhong University of Science and Technology Medical Science, 2016, 36(4): 514-518.
[28]	Liang P, Yu J, Lu MD, et al. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy [J]. World J Gastroenterol, 2013, 19(33): 5430.
[29]	Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans FrontiÃ¨res meeting 2013 [J]. European Radiology, 2015, 25(12): 3438-3454.
[30]	Leung U, Kuk D, D′Angelica MI, et al. Long-term Outcomes Following Microwave Ablation for LiverMalignancies [J]. British Journal of Surgery, 2015, 102(1): 85-91.
[31]	Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. [J]. Acta Oncologica, 2006, 45(7): 838-847.
[32]	Wulf J, Hädinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. [J]. Strahlentherapie Und Onkologie, 2001, 177(12): 645-55.
[33]	Hoyer M, Roed HHA, Ohlhuis L, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases [J]. Acta Oncologica, 2006, 45(7): 823-830.
[34]	Aitken KL, Hawkins MA. Stereotactic Body Radiotherapy for Liver Metastases [J]. Clinical Oncology, 2015, 27(5): 307-315.

[1]	高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2]	徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3]	刘一鸣, 温佳新, 赵恺, 薛志强. ⅢA 期肺腺癌新辅助治疗后胸腔镜右肺中下叶切除术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 311-313.
[4]	张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[5]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[6]	梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[7]	严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[8]	赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[9]	黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[10]	张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[11]	张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[12]	中国抗癌协会结直肠肿瘤整合康复专业委员会, 北京癌症防治学会直肠癌新辅助治疗专业委员会. 直肠癌新辅助治疗相关恶心、呕吐副反应的预防、诊断及治疗指南[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 353-361.
[13]	任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[14]	王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15]	崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Progress in neoadjuvant therapy of colorectal cancer liver metastasis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Progress in neoadjuvant therapy of colorectal cancer liver metastasis